Monday, June 05, 2017 10:00:37 AM
New funding is not enough to guarantee success against emerging infectious diseases around the world. Rather, good governance, a long-term technology investment strategy and strong product management skills are essential, say a Dartmouth College researcher and her co-author.
Their article appears in the journal Nature Biotechnology.
Kendall Hoyt, Ph.D., an assistant professor at the Geisel School of Medicine at Dartmouth and an expert in biosecurity, and Richard Hatchett, M.D., the acting director of the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services, propose a new way to develop countermeasures for Ebola, Zika and other emerging infectious diseases. As momentum builds for an international effort to develop drugs and vaccines for emerging infectious diseases, the duo examined U.S. biodefense programs to understand approaches that might work and developed a global strategy for countermeasure development.
"As infectious outbreaks such as SARS, MERS, Ebola and Zika become the new norm, there is growing recognition that governments and philanthropic organizations need to pool funds to develop countermeasures for these diseases," Hoyt says. "Money is not enough, however. Without strong governance, a clear technology strategy and good product management, precious public funds will be wasted and we will continue to battle public health emergencies of international concern without the aid of medical countermeasures."
In February, the World Health Organization declared the Zika virus a public health emergency, setting a now familiar scenario into motion. As with previous infectious disease outbreaks -- HIV/AIDS, severe acute respiratory stress (SARS) disorder, pandemic flu and most recently Ebola -- Zika will spark an international race to develop new vaccines.
"The problem is that vaccines can take over a decade to develop," Hoyt says. "The development of new biomedical countermeasures -- vaccines, therapies and diagnostic -- requires the coordination of a wide number of institutional and industry actors to succeed. We argue that international efforts to develop countermeasures for emerging infectious diseases should build on lessons learned from U.S. programs to develop closely related biodefense products."
Story Source:
Materials provided by Dartmouth College. Note: Content may be edited for style and length.
Recent AEMD News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/13/2024 09:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 12:01:40 PM
- Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma • PR Newswire (US) • 05/10/2024 12:01:00 PM
- Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices • PR Newswire (US) • 02/21/2024 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 10:15:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:41 PM
- Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 02/14/2024 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024 • PR Newswire (US) • 02/07/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:06:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:04:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:02:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:01:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 12:49:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:15:39 PM
- Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 11/14/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:01:36 PM
- Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer • PR Newswire (US) • 11/13/2023 01:01:00 PM
- Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023 • PR Newswire (US) • 11/06/2023 01:01:00 PM
- Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology • PR Newswire (US) • 10/10/2023 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 09:05:12 PM
- Aethlon Announces Reverse Stock Split • PR Newswire (US) • 10/04/2023 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:57:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:56:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:54:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 01:00:08 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM